Massachusetts Financial Services Co. MA Cuts Stock Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Massachusetts Financial Services Co. MA decreased its stake in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 2.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 193,762 shares of the biopharmaceutical company’s stock after selling 4,692 shares during the quarter. Massachusetts Financial Services Co. MA owned about 0.09% of Sangamo Therapeutics worth $168,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in SGMO. Meritage Portfolio Management increased its holdings in shares of Sangamo Therapeutics by 8.6% during the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 6,740 shares in the last quarter. State Board of Administration of Florida Retirement System grew its position in Sangamo Therapeutics by 61.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 23,650 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in Sangamo Therapeutics by 55.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 38,850 shares in the last quarter. Golden State Equity Partners raised its holdings in Sangamo Therapeutics by 35.2% in the third quarter. Golden State Equity Partners now owns 266,484 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 69,368 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Sangamo Therapeutics in the second quarter worth approximately $67,000. Hedge funds and other institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Trading Up 7.5 %

Shares of SGMO opened at $2.30 on Thursday. The firm has a fifty day simple moving average of $1.48 and a two-hundred day simple moving average of $0.94. The firm has a market cap of $479.89 million, a PE ratio of -3.07 and a beta of 1.10. Sangamo Therapeutics, Inc. has a 1-year low of $0.30 and a 1-year high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. The company had revenue of $49.41 million for the quarter, compared to the consensus estimate of $26.55 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. During the same quarter in the prior year, the company earned ($0.34) earnings per share. As a group, research analysts forecast that Sangamo Therapeutics, Inc. will post -0.52 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on SGMO. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research report on Thursday, November 14th. Barclays lifted their target price on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. Finally, StockNews.com raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, November 14th.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.